


Multiple Sclerosis Market Size in the 7MM was ~USD 25 Billion in 2022, estimated DelveInsight

Multiple Sclerosis Market

LAS VEGAS, NEVADA, UNITED STATES, March 27, 2024 /EINPresswire.com/ -- DelveInsight's "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.



Key Takeaways from the Multiple Sclerosis Market Research Report

- The key driver for the surge in market size is the rise in number of Multiple Sclerosis prevalent cases in the 7MM.
- As per DelveInsight's estimates, in 2022, the Multiple Sclerosis diagnosed prevalent cases in the United States were found to be approximately 723,557 cases which are expected to increase by 2034.
- Assessments as per DelveInsight's analysts showed that in the United States, out of the total cases, there were approximately 40,519 cases with Clinically Isolated Syndrome, 544,839 cases with Relapsing-Remitting MS (RRMS), 91,892 cases with Secondary-Progressive MS (SPMS), and 44,137 cases with Primary-Progressive MS (PPMS) in 2022.
- The leading Multiple Sclerosis Companies working in the market include Immune Response BioPharma Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, and others.
- Promising Multiple Sclerosis Pipeline Therapies in the various stages of development include rHlgM22, CNTO 1275, CC-97540, Fludarabine, Cyclophosphamide, Interferon beta-1a (Rebif), alemtuzumab, and others.
- March 2024: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Ocrelizumab and Fingolimod. This double-blind, double-dummy study will evaluate the safety and efficacy of

ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.

- March 2024: Juno Therapeutics announced a study of Phase 1 clinical trials for CC-97540, Fludarabine and Cyclophosphamide. The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS).

Discover which therapies are expected to grab the Multiple Sclerosis market share @ [Multiple Sclerosis Market Outlook](#)

Multiple Sclerosis Overview

Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In MS, body's own immune system produces cells and proteins (antibodies) attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions. The damaged myelin forms scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted.

Multiple Sclerosis Epidemiology Segmentation in the 7MM

- Gender-specific Cases
- Total Diagnosed Prevalent Cases
- Phenotype-specific cases
- Age-specific Cases
- Extent of Disability (EDSS)

Download the report to understand which factors are driving Car Multiple Sclerosis epidemiology trends @ [Multiple Sclerosis Epidemiological Insights](#)

Multiple Sclerosis Market Landscape

The major Multiple Sclerosis drug market is governed by the treatment to modify progression. This is usually by enhancing the progression free survival and increasing the quality-adjusted year of life. These are also referred as Disease Modifying Treatment (DMT) and is based on the four clinical phenotypes of MS.

Multiple Sclerosis Market Dynamics

The Multiple Sclerosis market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies by 2034.

Multiple Sclerosis Emerging Drugs Profile

- Masitinib (AB Science)
- CNM-Au8 (Clene Nanomedicine)
- Tolebrutinib (SAR442168) (Sanofi)

- IMS001 (T-MSC) (ImStem Biotechnology)

Multiple Sclerosis Treatment Landscape

Multiple Sclerosis treatment has two aspects: disease-modifying therapy (DMT) for the underlying immune disorder, and therapies to relieve or modify symptoms. Disease-modifying agents are directed towards reducing the frequency of relapses and slowing progression. DMT has been approved for use only in relapsing forms of MS. Among patients with MS who switched DMTs, persistence was consistently low regardless of treatment. Although persistence with oral DMTs was slightly higher than with injectable DMTs, overall results indicate poor persistence to second-line therapy and highlight the need to improve long-term persistence with DMTs. The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat MS. Various companies are developing therapies including CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), and many others which are expected to enter the 7MM market by 2034.

Multiple Sclerosis Drugs Uptake

Tolebrutinib, also known as SAR442168 is being developed by Sanofi. Tolebrutinib is an investigational brain-penetrant and bioactive Bruton's tyrosine kinase (BTK) inhibitor that achieves CSF concentrations predicted to modulate B lymphocytes and microglial cells. Further, it blocks the BCR-mediated activation ($IC_{50} = 10 \text{ nM}$) and Fc receptor activation of immune cells. The drug is being studied in three Phase III trials for the treatment of Relapsing MS, PPMS, and SPMS.

Masitinib developed by AB Science is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of PMS. It modulates the activity of mast cells and macrophages, important cells for immunity, through targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Currently, the drug is in Phase III for the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.

CNM-Au8 (Clene Nanomedicine) is a concentrated, aqueous suspension of clean surfaced faceted nanocrystalline gold (Au) that acts catalytically to support various intracellular biological reactions and restore neuronal health and function by increasing energy production and utilization. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical-grade water. The drug is currently being evaluated in Phase II and II/III studies for the treatment of MS and stable relapsing MS, respectively.

IMS001 (T-MSC) developed by ImStem Biotechnology is a human embryonic cell (hESC) derived mesenchymal stem cell (MSC) investigational drug. T-MSC is based on ImStem's patented technology, which can differentiate hESCs into MSCs with high efficiency, consistency, and quality, through a trophoblast-like intermediate stage. It is the first hES-MSC, intravenously delivered, allogeneic off-the-shelf stem cell therapy being investigated for MS in Phase I clinical

trial, however as per company's pipeline the therapy is under Phase IIa development.

Scope of the Multiple Sclerosis Market Report

- Coverage- 7MM
- Study Period- 2019-2032
- Multiple Sclerosis Companies- Immune Response BioPharma Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, and others.
- Multiple Sclerosis Pipeline Therapies- rHlgM22, CNTO 1275, CC-97540, Fludarabine, Cyclophosphamide, Interferon beta-1a (Rebif), alemtuzumab, and others.
- Multiple Sclerosis Market Dynamics: Multiple Sclerosis Market Drivers and Barriers

Discover more about Multiple Sclerosis Drugs in development @ [Multiple Sclerosis Ongoing Clinical Trials Analysis](#)

Table of Content

1. Key Insights
2. Report Introduction
3. Multiple Sclerosis Market Overview at a Glance
4. Multiple Sclerosis Executive Summary
5. Multiple Sclerosis Market Disease Background and Overview
6. Multiple Sclerosis Treatment
7. Multiple Sclerosis Management
8. Guidelines
9. Multiple Sclerosis Epidemiology and Patient Population
10. Patient Journey 1
11. Patient Journey 2
12. Multiple Sclerosis Emerging Therapies
13. Other Multiple Sclerosis Emerging Drugs
14. Multiple Sclerosis Marketed Therapies
15. Multiple Sclerosis: 7 Major Market Analysis
16. Multiple Sclerosis Market Outlook
17. Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US
18. Multiple Sclerosis KOL Views
19. Multiple Sclerosis Unmet Needs
20. Multiple Sclerosis Market Drivers
21. Multiple Sclerosis Market Barriers
22. Multiple Sclerosis SWOT Analysis
23. Appendix
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj

DelveInsight

+91 96502 13330

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/699136216>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.